The successful application of ABO-incompatible (ABO-i) kidney transplantation has led to a growing interest in its application to lung transplantation (LTx), as it may alleviate potential organ shortages. Worldwide, LTx rates have decreased during the COVID-19 pandemic, which has had a significant impact on waiting list mortality. According to the National Institute of Health's 2022 annual report, LTx accounted for only 3.6% of all transplants in Colombia [1].